Powerpoint : breast cancer

BREAST CANCER

EpidemiologyBreast cancer is the most prevalent cancer among

women and affects approximately one million women worldwide.

Prevalence ( epidemiology) is the total number of cases of a disease in a given population at a specific time

Prevalence is the number of all new and old cases of a disease during a particular period.

Incidence is the number of new cases of a disease diagnosed in one year.

EpidemiologyBreast cancer accounts for 30% of all female

cancers (UK). Men can also develop breast cancer,

accounting for 1% of cases diagnosed annually (UK).

Breast cancer is the most common cause of cancer in women (U.S.)

The most common cause of death in women between the ages of 45 and 55 (U.S.)

RISK FACTORS

SexBC in men is rare (> 1% from all malignant

tumors)Sex ratio, women / men = 100 : 1

Age

Ageing is the most important RF

RISK FACTORS

Geographical variation

There is quite a difference in incidence rate of breast cancer between different countries.

The biggest difference is between Eastern and Western countries - low to high

RISK FACTORSReproductive factors- Women who start menstruating early in life

orwho have a late menopause have an

increased risk of breast cancer. - Women who have natural menopause after

the age of 55 are twice as likely to develop breast cancer then women who experience the menopause before the age of 45.

RISK FACTORS

Age at first pregnancy Having no children and being older at the

time of the first birth both increase the incidence of breast cancer.

The risk of breast cancer in women who have their first child after the age of 30 is about twice that of women having their first child before the age of 20.

The highest risk group are those who have their first child after the age of 35

RISK FACTORS

Inherited risk Up to 10 % of breast cancer in Western

countries is due to an inherited factor.It is not yet known how many breast cancer

genes there are, but to date, two specific breast cancer genes have been identified (BRCA1 and BRCA2).

RISK FACTORSPrevious breast disease Women with certain benign changes in their

breasts - severe atypical epithelial hyperplasia. Radiation Women who received radiation to the chest as a

result of repeated X-rays for tuberculosis, age 10 and 14 years.

Women with Hodgkin's disease who received radiation therapy to the chest have an excess risk of breast cancer.

RISK FACTORSHormone replacement therapyAmong current users of

hormone replacement therapy (HRT) and those who have stopped using it one to four years previously, there is an increased risk of breast cancer.

This increased risk is very similar to the effect of a delay in the menopause by one year.

RISK FACTORSWeightBeing overweight is associated with a doubling of

the risk of breast cancer in postmenopausal women whereas amongst premenopausal women obesity is associated with reduced breast cancer incidence.

Alcohol intakeSome studies have shown a link between the amount

of alcohol people drink and the incidence of breast cancer, but this relationship is not consistent and may be influenced by dietary factors other than alcohol.

RISK FACTORSHormonesWomen who take the contraceptive pill are

at a slight increased risk while they take the Pill and they remain at risk for 10 years after stopping the drugs.

SYMPTOMS AND SIGNSPainless lump in the breastChange in the skin

DimplingFixityOrange peel

Change in the nippleRetractionEczema- ( Paget’s )

Painless lump in the axilla

INVESTIGATIONSMammographyBreast ultrasoundFNACCore biopsyOpen biopsyMRICXRAbdominal ultrasoundBone scintigraphy

MAMMOGRAPHY

Mammograms are a good way of identifying abnormalities in the breast.

Used for women over the age of 35.

In younger women the breast tissue is more dense, which makes it difficult to detect any changes on the mammogram.

MAMMOGRAPHYHowever, mammograms are not perfect:

A mammogram may miss some cancers. (The result is called a "false negative.")

A mammogram may show things that turn out not to be cancer. (The result is called a "false positive.")

Breast cancer-mammogram

BREAST ULTRASOUND SCANAn ultrasound uses sound waves to build up a

picture of the breast tissue.

Ultrasound can often tell whether a lump is solid (made of cells) or a fluid-filled cyst.

It can also often gives the information whether a solid lump is likely to be benign or malignant

FNACWill show whether the lump is full of fluid or solid.

Can allow a sample of cells to be removed for examination under the microscope –cytology.

This is a very accurate method of finding out whether the lump is benign or malignant.

A fine needle aspiration (FNA) is a quick, simple procedure done in the outpatient clinic

NEEDLE CORE BIOPSYCan allow a breast tissue specimen for

histological and immunohistochemistry exam.

Can obtain a preoperative diagnosis resulting in more appropriate decision of therapy.

Core biopsies are often done using ultrasound as guide to the lump.

Local anaesthetic is injected into the area first to numb it

OPEN BIOPSYA biopsy is the only way to tell for sure if cancer is

present.

An incisional biopsy takes a sample of a lump or abnormal area.

An excisional biopsy takes the entire lump or area.

This procedure is done either under local anaesthesia or general anaesthesia.

OTHER INVESTIGATIONS

CHEST X RAY

ABDOMINAL ULTRASOUND

CT OF THE BRAIN

BONE SCINTIGRAPHY

Types of breast cancer

Early pathologists classified breast cancers into 'invasive ductal' cancers and 'invasive lobular' cancers, believing that invasive ductal cancers arose in ducts and invasive lobular cancers in the lobules.

A more logical classification divides tumours into those of 'special' and 'no special' type.

Types of breast cancersInvasive carcinoma of no special type is also

commonly referred to as invasive ductal carcinoma. It is the most common type and accounts for up to 85

% of all breast cancers.

Special types of tumour have particular microscopic features and these include invasive lobular carcinoma, invasive tubular, cribriform, medullary and mucinous cancers.

Many of the special-type cancers have a better prognosis - in other words the patient has a higher chance of survival.

Stage Information

The American Joint Committee on Cancer (AJCC) staging system provides a strategy for grouping patients with respect to prognosis.

Therapeutic decisions are formulated in part according to:- staging categories - lymph node status,

- estrogen- and progesterone-receptor levels in the tumor tissue,

- menopausal status, - the general health of the patient.

TNM AJCC/UICC 2002 - CLASSIFICATIONT (primary tumour))

Tx primary tumour cannot be assessed To without primary tumourTis in situ (DCIS/ LCIS), Paget’s of the nipple

T1 < 2 cm T1a ≤ 0.5 cm

T1b 0.5-1 cm T1c > 1 cm

T2 2 cm - 5 cm T3 > 5 cmT4 any size with invasion to the chest wall/skin

T4a invasion to the chest wallT4b oedema, orange peel, satellite nodulesT4c T4a + T4bT4d carcinomatous mastitis

StagingN (lymph nodes, LN)pN → pN → ≥ 10 ≥ 10 examined LN examined LNNx cannot be assessedNo no LNN1 mobile ipsilateral LNN2 fixed ipsilateral LN N3 subclavicular, internal mammary, supraclavicular

LN

M (distant metastases, MTS )M0 absent MTS M1 present MTS

TNM staging

Stage I T1 No Mo

Stage IIA To-1 N1 MoT2 No Mo

Stage IIB T2 N1 MoT3 No Mo

Stage IIIA To-2 N2 MoT3 N1-2 Mo

Stage IIIB T4 No-2 MoStage IIIC any T N3 M0

Stage IV any T any N M1

Staging of the breast malignant tumour Stage 0 Ductal carcinoma in situ (DCIS) almost always completely

curable.

The following stages of breast cancer are known as invasive breast cancer: Stage 1 The tumour measures less than 2cm. The lymph nodes in the

axilla are not affected and there are no signs that the cancer has spread elsewhere in the body.

Stage 2 The tumour measures between 2 and 5cm. or the lymph nodes in the axilla are affected, or both. However, there are no signs that the cancer has spread further.

Stage 3 The tumour is larger than 5cm. and may be attached to surrounding structures such as the muscle or skin. The lymph nodes are usually affected.

Stage 4 The tumour is of any size, but the lymph nodes are usually affected and the cancer has spread to other parts of the body. This is metastatic breast cancer.

Credit line: Breast. In: Greene, F.L., Compton, C.C., Fritz, A.G., et al., editors. AJCC Cancer Staging Atlas. New York: Springer, 2006: 219-233. ©American Joint Committee on Cancer.

Tis – Paget,s of the nipple


T1mic – microinvasion ≤ 0.1 cm.


T1 - ≤ 2 cm. T1a – > 0.1 cm - 0.5 cm; T1b –> 0.5 cm - 1 cm; T1c – > 1 cm - 2 cm.


T2 - > 2 cm - 5 cm T3 – > 5 cm.


T4a - any size with direct invasion to the chest wall.


T4b –any size with direct invasion to the skin, orange peel, skin ulcer, satellite nodule.


T4c = T4a + T4b.


T4d – inflammatory carcinoma


pN0 – no lymph node MTS.


pN1mi - > 0.2 - 2.0 mm,

pN1a – meta in 1-3 LN

pN1b – meta int. mammary LN

pN1c – N1a+N1b

pN2 – meta 4-9 LN

Hormone receptors

Many breast cancers have receptors for the hormone oestrogen.

When oestrogen attaches to these receptors, it causes the cancer cells to grow.

If a breast cancer has a significant number of oestrogen receptors it is known as being oestrogen-receptor positive ER+

If it doesn’t it is known as oestrogen-receptor negative ER-

Knowing whether the tumour has oestrogen receptors or not helps the doctors to decide on the best treatment.

Hormone receptors

A tumour that is ER+ is likely to respond to hormonal treatments|, whereas a tumour that is ER- will not respond.

Some breast cancers have progesterone receptors and are known as progesterone-receptor positive (PR-positive).

Usually, cancers that are ER+ will also be PR+.

Progesterone receptors are less important than oestrogen receptors in predicting the likely response to hormone treatment.

HER2 receptors

Some cancers have receptors for a protein known as HER2|.

Tumours that have high levels of these receptors are known as HER2-positive and may respond to treatment with drugs such as trastuzumab (Herceptin®)|.

HER2 is a protein found on the surface of certain cancer cells.

Some breast cancers have a lot more HER2 receptors than others.

In this case, the tumour is described as being HER2-positive.

HER2 receptors

Tumours that are HER2-positive tend to grow more quickly than other types of breast cancer.

Knowing if a cancer is HER2-positive can sometimes affect the choice of treatment.

Women with HER2-positive breast cancer can benefit from a drug called trastuzumab (Herceptin®).

Herceptin only works in people who have high levels of the HER2 protein.

MANAGEMENTMultidisciplinary

PacientGPSurgeonRadiologistPatologistOncologist RadiotherapistSystematicSymptoms, history Physical examinationImaging investigations Biopsy (type, grading, markers)

EconomicWork

together.

Treatment overview

The treatment of breast cancer is individual for each woman.

The treatment depends on many factors, including: the stage and grade of the cancer age whether the cancer cells have receptors for certain

hormones (such as oestrogen) or particular proteins (such as HER2).

Treatment overviewMost primary breast cancers will be treated

with surgery.

All or part of the breast tissue may be removed.

If the whole breast is removed (mastectomy),

Breast reconstruction may be carried out, either at the same time as the initial surgery or later.

Treatment overview

Sometimes chemotherapy| or hormonal therapy| may be given to shrink a cancer before surgery -this is known as neo-adjuvant therapy.

After surgery, radiotherapy| will be given to any remaining breast tissue, and may be given to the chest wall if the breast has been removed. This is to make sure that any cancer cells that may be left in the area are destroyed.

Further treatment includes hormonal therapies, chemotherapy and/or a drug called Herceptin|®.

Factors which affect the chance of the cancer coming backthe size of the tumour

lymph nodes status

the grade of the tumour

Receptor status for oestrogen or particular proteins (such as HER2) Cancers with oestrogen receptors are less likely to recur in the short term, whereas those with HER2 receptors are more likely to come back unless Herceptin is given.

SurgerySegmental excision (breast-conserving

surgery or breast-sparing surgery) Followed by radiotherapy aimed to destroy cancer

cells that may remain in the breast.

Mastectomy – excision of the whole mammary glandStudies have found equal survival rates for breast-

sparing surgery (with radiation therapy) and mastectomy for Stage I and Stage II breast cancer.

Breast-conserving surgery

Segmental excision – excision of a quadrant till MP muscle

This is usually followed by radiotherapy, treatment to the remaining breast tissue.

The pathologist looks to see whether there is an area of healthy cells all around the cancer – this is known as a clear margin.

If there are cancerous or precancerous (DCIS) cells at the edge of the area of breast tissue that has been removed, there is a higher chance that the cancer will come back in the breast.

In this case, more breast tissue will need to be removed or even a mastectomy.

STAINING WITH CHINA INK TO ASSESS THE MARGINS OF RESECTION

FREE OF TUMOUR CELLS / PRESENT TUMOUR CELLS

Radical surgery

Removal of the whole breast (mastectomy) may be necessary if: The breast lump is large in proportion

to the rest of the breast tissue. There are several areas of cancer cells

in different parts of the breast- multicentricity of the tumour.

The lump is just behind the nipple

Mastectomy

Simple mastectomy and sentinel node biopsy or node sampling removes the breast tissue and the lower lymph nodes, within the axilla.

Sentinel lymph node biopsy is a new method of checking for cancer cells in the lymph nodes. A surgeon removes fewer lymph nodes, which causes fewer side effects. (If there are cancer cells in the sentinel lymph node, an axillary lymph node dissection usually is done.)

Modified radical mastectomy removes all the breast tissue and all of

the lymph nodes in the axilla. It may also be referred to as a total mastectomy and axillary clearance.

Radical mastectomy removes all the breast tissue and the lymph nodes in the axilla, together with the muscles behind the breast tissue. This is only done if the cancer invaded the pectoralis muscles.

Surgical complicationsLocal pain and tenderness- pain relief with

painkillersWound infectionBleeding wound

Numbness and tingling of the shoulder and upper arm due to nerve damage during axillary dissection

Lymphedema of the arm due to impaired lymph drainage following axillary dissection.

Radiotherapy for breast cancer

Radiotherapy treats cancer by using high-energy rays to destroy the cancer cells.

The treatment is often used after surgery for breast cancer, most commonly after segmental excision.

It may occasionally be used before, or instead of, surgery.

Radiotherapy can cause side effects such as: skin soreness and tiredness, but most will improve once the treatment has

finished.

Radiotherapy for breast cancer

After a mastectomy, radiotherapy to the chest wall may be given if there is a risk that any cancer cells have been left behind.

If a few lymph nodes have been removed and these contained cancer cells, or if no lymph nodes have been removed, radiotherapy may be given to the axilla to treat the remaining lymph nodes.

If all the nodes have been removed from the axilla, radiotherapy to this area is not usually needed.

Chemotherapy for breast cancer

Chemotherapy is the use of anti-cancer (cytotoxic) drugs to destroy cancer cells.

The aim of chemotherapy is to do the maximum damage to cancer cells while causing the minimum damage to healthy tissue.

Indications: Before surgery to shrink the cancer. This is

known as neo-adjuvant chemotherapy. After surgery if doctors think there is a risk of

the cancer coming back. This is known as adjuvant chemotherapy.

ChemotherapyThere are many different chemotherapy drugs used to treat

breast cancer, and they are often used in combinations (called a chemotherapy regimen).

The commonly used chemotherapy drugs include: cyclophosphamide epirubicin fluorouracil (5FU) methotrexate paclitaxel (Taxol) doxorubicin (Adriamycin®) docetaxel (Taxotere®).

Hormonal therapies for breast cancer

Hormonal therapies are treatments to reduce the levels of hormones in the body or block their effects on cancer cells.

They are often given after surgery, radiotherapy, and chemotherapy for breast cancer, to reduce the chance of recurrence.

Hormonal therapies are only effective in women whose cancer cells have receptors for oestrogen and/or progesterone on their surface.

This is known as being oestrogen-receptor positive (ER+) or progesterone-receptor positive (PR+).

Hormonal therapy for postmenopausal womenPostmenopausal women may be offered hormonal

treatment with either an anti-oestrogen (such as tamoxifen) or an aromatase inhibitor (such as Arimidex®).

Tamoxifen has been the most widely used hormonal therapy for breast cancer and has been shown to be highly effective in reducing the chance of the cancer coming back.

Research has shown that for some women, giving aromatase inhibitors instead of tamoxifen, or after a period of tamoxifen treatment, can further reduce the chance of the cancer coming back.

Hormonal therapy for premenopausal women

Premenopausal women may be offered hormonal treatment with: an anti-oestrogen drug (such as tamoxifen) Treatment to stop the ovaries from producing

oestrogen (ovarian ablation). This can be done using surgery, radiotherapy, or a drug called goserelin (Zoladex® ).

Unfortunately, ovarian ablation by surgery or radiotherapy brings on an early menopause, which can be very upsetting, especially for women who were hoping to have children. The effects of medicines are usually temporary.

Biological therapy - Herceptin® (trastuzumab) for breast cancer

Trastuzumab| ( Herceptin®) is a monoclonal antibody.

It works by attaching to HER2 receptors (proteins) on the surface of breast cancer cells.

This stops the cancer cells from dividing and growing. Herceptin can reduce the chance of breast cancer to

recur after initial treatment for early breast cancer. However, it is only effective for women whose breast

cancer cells have a large number of the HER2 receptors on their surface. This is known as being HER2-positive. Around 1 in 5 women (20%) with breast cancer are HER2-positive.

Biological therapy - Herceptin®Side effects are usually mild, but some women may

have: flu-like symptoms, diarrhoea , headaches , allergic reaction.

In some women, Herceptin may cause damage to the heart muscle, which could lead to heart failure.

If this happens the Herceptin® will be stopped. Usually, the effect on the heart is mild and reversible.

Therapeutical categoriesAccording to the first treatment:

Surgical/non-surgical cancer

Surgical breast cancer

Stages - 0, I, II, partial IIIA (T3 N1) Initial therapeutic step - surgery

Post-operatively: treatment according to type/grade

and tumoral receptors

Therapeutic categoriesInoperabile cancer

Stages IIIA (T0-3 N2), IIIB (T4 N0-2) şi IIIC (T0-3 N3)

Therapeutic goal – palliation, improve QOL

Initial step – systemic therapy

(CHT/HT/biological)

Good response → surgery-mastectomy→ radioterapie

(RT)

Bad response → RT (DT = 50 Gy)

Therapeutic categoriesMetastatic or recurrent cancerStage IV (T0-4 N1-3 M1)

Therapeutic goal:PalliationCure- Local recurrence

Initial step:Systemic therapy orRTE, after surgical removal of local recurence if possible

LOCALLY ADVANCED BREAST CANCER

ESMO 2008 Recommandations

Systemic neo-adjuvant therapy

Radiotherapy

Surgery

Post-op. systemic therapy

Breast cancer- Case report

P.A., female, aged 50, Iasi

PRESENT COMPLAINT- upper outer quadrant painless lump in the right breast with enlarged axillary lymph nodes - december 2001.

HISTORYno family history of cancersfirst period: age 12, last period: may 2002; pregnancies: 2 (age 28, 31), abortions: 2no personal history of relevant diseases/ hospital

admissions

DIAGNOSIS

May 2002 Surgery Unit admission/ clinical

evaluation: 3.5/4 cm mass in the upper outer

quadrant of the right breast, slightly adherent to skin

associated fixed, matted right axillary lymph nodes

Fine-needle aspiration biopsy: malignant cytology

TREATMENT (I)

August 2002Surgery – quadrantectomy + axillary clearancePathology report: invasive ductal carcinoma,

pT1 N1a M0 G2 L1 V1- 1/1 cm tumor, negative resection limits - 3 out of 10 axillary lymph nodes with large

metastasis- invasion of the subcutaneous tissue, vascular

emboli, no perineural invasionImmunehistochemistry report: ER positive (35%), PR positive (50%)HER 2 neu negative (1+)

Postoperative treatment

September 2002Oncology admission/ clinical evaluation:

Biologic work-up – normal Postoperative thoracic scar – normal aspect Abdominal ultrasound, chest X-ray – no apparent

secondary lesions

QUESTION 1

HOW WOULD YOU TREAT?

A. Start adjuvant chemotherapy (anthracycline-based regimen) + radiation therapy + hormone therapy

B. Start adjuvant chemotherapy (CMF regimen) + hormone therapy

C. Start adjuvant radiation therapy + hormone therapy

D. Initiate adjuvant hormone therapy: tamoxifen

E. Initiate adjuvant hormone therapy: aromatase inhibitors

TREATMENT (II)October-December 2002

Adjuvant chemotherapyCA protocol – cyclophosphamide 600 mg/m2 +

adriamycin 60 mg/m2, 3-weekly schedule, 4 cycles

January-March 2003Adjuvant radiation therapy

conventional irradiation, TD 44 Gy/22 fr., tumor bed + axillary field

March 2003Adjuvant hormone therapy

tamoxifen 60 mg/day

2003-20053-monthly evaluations (clinical, biologic and

imagistic)no signs of disease progression

February 2005Clinical evaluation:

progressively worsening low-back and right leg pain.

Lumbar spine X-ray: dorso-lumbar scoliosis reduction of the L3-L4 intervertebral space no aspects suggestive of bone metastases

QUESTION 2

WHICH ARE THE APPROPRIATE STEPS?

A. Order a bone scan

B. Recommend lumbar magnetic resonance imaging (MRI) to exclude spinal cord compression

C. Prescribe nonsteroidal anti-inflammatory medication (NSAIDs)

D. Evaluate serum and urine protein electrophoresis

E. Perform a CT-guided biopsy

February-July 2005NSAID treatment

Pain diminished in intensity, still not controlled

July 2005Bone scan:

Multiple sites of pathologic increased uptake: skull, vertebral spine, bone pelvis, clavicle, right humerus, left femur, left tibia – bone metastases

QUESTION 3


A. Start 2nd line hormone therapy (aromatase inhibitors)

B. Initiate 2nd line chemotherapy (taxanes) + bisphosphonates

C. Start 2nd line chemotherapy + 2nd line hormone therapy + bisphosphonates + palliative radiation therapy

D. Recommend orthopedic surgery for internal fixation

E. Initiate palliative radiation therapy

TREATMENT (III)July 2005

Palliative radiation therapy conventional irradiation, TD 20 Gy/4 fr., anterior

femoral field! during irradiation – pathologic fracture: left femur,

medium third

Orthopedic surgery – osteosynthesis by metallic rigid nail

Starts 2nd line hormone therapy letrozol 2.5 mg/day

Starts bisphosphonates pamidronat 60 mg/day I.V., on a monthly basis

Continues pain therapy NSAIDs tramadolum P.O. 50 mg bid

September 2005Clinical evaluation:

pain controlled

Liver work-up – modified: γGT = 204 UI/l

Abdominal ultrasound: Liver – hipoechogenic nodules, segment 6 = 3.4 cm;

segment 8 = 2 cm; segment 2 = 1.8 cm (metastases)

QUESTION 4

WHAT IS THE NEXT TREATMENT STEP?

A. Start 2nd line chemotherapy (capecitabine/ docetaxel/ liposomal doxorubicin)

B. Start 3rd line hormone therapy

C. Consider transarterial hepatic chemoembolization (CHEAT)

D. Consider surgical resection of hepatic lesions

E. Best supportive care

TREATMENT (IV)October 2005

Starts 2nd line chemotherapy capecitabine 1250 mg/m2 x 2 P.O., D1-14, 3-weekly

scheduleContinues 2nd line hormone therapy (letrozol)bisphosphonates (pamidronat), unchanged dosage and

schedule.

December 2005Clinical evaluation:

ECOG PS 1, lumbar pain relatively controlledLiver work-up – normal:

γGT = 33 UI/lAbdominal ultrasound:

Liver metastases – segment 6 = 2.7 cm, segment 8 = 2.9 cm, segment 2 = 2.0 cm (stable disease)

January 2006 Left femur X-ray:

Median osteoblastic cortical bone lesion (posttraumatic pathological bone lesion?)

Lumbar spine X-ray: Osteoblastic bone lesions of the L1 vertebral body

(slightly collapsed) and the L2 right vertebral pedicle

Bone pelvis X-ray: Osteoblastic bone lesions of the right ramus ischium

(2 cm) and of the lateral aspect of the left sacro-iliac articulation (diffuse)

QUESTION 5


A. Palliative radiotherapy

B. Start 3rd line chemotherapy

C. Consider an orthopedic intervention

D. Continue hormone therapy

E. Consider all the above mentioned options

TREATMENT (V)February 2006

Palliative radiation therapy conventional irradiation, TD 20 Gy/5 fr., dorso-

lumbar vertebral field

Continues 2nd line chemotherapy (capecitabine), 2nd line hormone therapy (letrozol) and bisphosphonates (pamidronat), unchanged dosage and schedule

Continues pain therapy NSAIDs tramadolum P.O. 50 mg tid

May 2006Clinical evaluation:

pain controlledAbdominal ultrasound:

Liver metastases – segment 6 = 2.8 cm; segment 8 = 1.8 cm; segment 2 = 1.9 cm (stable disease)

September 2007 Clinical evaluation:

ECOG PS 1, pain controlledAbdominal ultrasound:

Liver metastases – stable disease Dorso-lumbar spine X-ray:

Multiple osteoblastic bone lesions (D7-D12, L1-L2, iliac bones, sacrum)

Left femur X-ray: Osteosynthesis nail overpasses the femoral head by

approximately 2 cm

March 2008Clinical evaluation:

pain controlledAbdominal ultrasound:

Liver – stable disease Bone X-rays:

stable disease

TREATMENT (present)Continues 2nd line chemotherapy (capecitabine), 2nd

line hormone therapy (letrozol) and bisphosphonates (pamidronat), unchanged dosage and schedule

Continues pain therapy NSAIDs tramadolum 100 mg bid

Powerpoint : breast cancer

Documents

Transcript of Powerpoint : breast cancer